David Bajor News Today

With a new $2 million federal grant, a researcher with the Case Western Reserve University School of Medicine will lead a team to further explore preliminary fi

UH Seidman Cancer Center conducting several clinical trials relating to the disease.

A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions.

A drug currently used in just 1% of cancers has significant potential against the remaining 99%, according to a new study from UH Seidman Cancer Center and Case

Researchers at the Case Western Reserve University School Medicine have found that combining two cancer drugs can be effective in treating a specific type of colorectal cancer, according to a new study published in Nature Communications.